TScan Therapeutics, Inc. (TCRX) stock
TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15−0.00 (-1.72%)
Close on Nov 18, 2026Market cap $10.06MP/E –Yield –
TScan Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
TScan Therapeutics's price to sales ratio was 3.4× on Nov 11, 2026, against 16.8× a year earlier. Over the last 4 years it ranged from 2.0× to 83.5×, with a median of 15.3×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 3.4× | −11.7 |
| 2025 | Dec 31, 2025 | 15.1× | −19.1 |
| 2024 | Dec 31, 2024 | 34.3× | +17.9 |
| 2023 | Dec 29, 2023 | 16.4× | +12.9 |
| 2022 | Jan 31, 2022 | 3.5× | +0.2 |
| 2021 | Dec 31, 2021 | 3.3× | – |
See a number that looks wrong?